Over the years, extensive R&D efforts have established
the basis for a wide range of microbiome-based therapeutic and diagnostic products,
which may cause a paradigm shift in the way healthcare is delivered in the
foreseen future
Roots Analysis
The concept of
microbiome-based therapeutics has generated significant enthusiasm within the
medical science community, defining a new frontier in the field of medicine. Despite
having captured the interest of several venture capital firms and big pharma
players, no microbiome-based therapeutic has been officially approved by an
authorized medical product regulator. However, the current development pipeline
of microbiome therapeutics has several promising candidates that are likely to
result in commercial success stories soon.
To order this 640+
page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
Key Market Insights
260
therapy candidates are currently in different phases of development
Nearly 25% of
pipeline drugs are in the clinical phase of development, while the rest are in the
preclinical / discovery stage. Interestingly, most of these drugs target digestive
and gastrointestinal disorders (20%); this is followed by product candidates intended
for treatment of oncological disorders (17%) and infectious diseases (13%).
Over
30 microbiome diagnostic tests are currently available / under development
Around
30% of the abovementioned tests have been commercialized, while the rest are
under development. Of the total tests, notable examples of companies that launched
a microbiome-based diagnostic solution include (in alphabetical order)
ARTPred, Genetic Analysis, Goodgut, Invivo Healthcare, IS-diagnostics, Luxia
Scientific and Varinos.
FMTs
are the only commercially available microbiome therapy
This
therapeutic product is presently indicated for the treatment of recurrent Clostridium
difficile infections (rCDIs). Further, non-industry players (such as
University of Alberta, The Second Hospital of Nanjing Medical University,
University of California and Chinese University of Hong Kong) are making
notable contributions in this arena, having been involved in ~200 clinical
trials till August 2019.
51%
growth in capital investments has been observed since 2015; around 70%
investment has come from Venture Capital investors
It
is worth noting that more than 80 investors have supported the R&D programs
initiated by start-ups focused on microbiome-related products. Well-funded start-ups have initiated product
development programs, having invested significant time and effort to explore
the applicability of microbiome therapeutics across various indications.
Several
big pharma players have microbiome-related initiatives
Leading
pharmaceutical companies have actively partnered with smaller business entities
to develop capabilities related to microbiome-based therapies / diagnostics. Examples
of small ventures that have received support from big pharma players include
Assembly Biosciences, Enterome Bioscience, Finch Therapeutics and NuBiyota.
Contract
service providers have become an integral part of the microbiome supply chain
Presently,
certain firms claim to offer a wide array of contract research / manufacturing
services for microbiome therapeutics. Examples of such players include Adare
Pharmaceuticals, Biose, Cobra Biologics, CoreBiome, List Biological
Laboratories, NIZO, ProDigest, Quay Pharma and Wacker Chemie.
North
America and Europe are anticipated to capture over 85% of the market share by
2030
As late
stage products are commercialized, the microbiome therapeutics market is likely
to grow at an annualized growth rate of over 30%, during the next decade. In
addition to North America and Europe, the market in China / broader Asia
Pacific region is also anticipated to grow at a relatively faster rate.
To request a sample
copy / brochure of this report, please visit this- https://www.rootsanalysis.com/reports/281/request-sample.html
Key
Questions Answered
§
§ What
are the key technology platforms (available / under development) for microbiome-related
therapies and diagnostics?
§
§
§ Who
are the leading (industry and non-industry) players involved in the development
of FMT products?
§
§ What
is the trend in capital investments in microbiome-related R&D?
§ What
are the contributions of big pharma players in this domain?
§ Which
are the popular players offering big data-related services / tools to support
microbiome research?
§
The USD 4 billion (by 2030) financial opportunity
within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has
been analyzed across the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§ Others
§
§
§
§
The report features
inputs from eminent industry stakeholders, according to whom innovation in
microbiome-related research is mostly being driven by start-ups / small-sized companies.
The report includes detailed transcripts of discussions held with the following
experts:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The research covers
detailed profiles, featuring a brief company overview, its financial
information (if available), product
portfolio details (such as status of development of pipeline candidates,
clinical trial information and analysis of key trial end-points), recent
developments and an informed future outlook.
§
§
§
§
§
§
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1. Antibody Drug
Conjugates Market (5th Edition),
2019-2030
2.
3.
4.
Contact:
Gaurav Chaudhary
+1
(415) 800 3415
